drugset / Trial / NCT00812058

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

NCT00812058

Phase 2 Completed 180 enrolled Repligen Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.

Timeline

Start
2008-11
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Uridine Small molecule 2 g Oral

Indications